PubRank

P Hokland

Author PubWeight™ 65.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003 4.31
2 Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications. Leukemia 2006 1.74
3 Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992 1.59
4 Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998 1.42
5 [Granulocyte-macrophage colony-stimulating factor. Treatment of patients with highly malignant lymphomas and acute lymphoblastic leukemias after autologous bone marrow transplantation]. Ugeskr Laeger 1992 1.38
6 Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer 2012 1.24
7 Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 2000 1.22
8 Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med 1983 1.16
9 Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 1999 1.07
10 Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes. J Immunol 1981 1.04
11 DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 2000 0.99
12 Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenström's macroglobulinaemia. Br J Haematol 1987 0.99
13 [Blood transfusion increases the risk of surgical infection]. Ugeskr Laeger 1993 0.96
14 Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood 1984 0.96
15 Natural killer cell activity correlates with the amount of beta 2-microglobulin on human peripheral blood lymphocytes. Cell Immunol 1982 0.96
16 Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. Br J Cancer 1994 0.95
17 Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells. J Natl Cancer Inst 1988 0.95
18 Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res 1984 0.91
19 Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol 1985 0.89
20 An improved technique for obtaining E rosettes with human lymphocytes and its use for B cell purification. J Immunol Methods 1976 0.89
21 Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia. Br J Cancer 2002 0.89
22 Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2002 0.88
23 Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999 0.88
24 [Extramedullary manifestations among adult patients with acute lymphoblastic leukemia (ALL)]. Ugeskr Laeger 1991 0.88
25 Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. In Vivo 1999 0.87
26 Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 2013 0.87
27 Two small lymphocyte subpopulations in human peripheral blood. I. Purification and surface marker profiles. Int Arch Allergy Appl Immunol 1978 0.86
28 13-cis retinoic acid treatment of myelodysplastic syndromes. Leuk Res 1987 0.86
29 Breast tumour as a first manifestation of extramedullary relapse in acute lymphoblastic leukaemia. Scand J Haematol 1984 0.84
30 Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells. J Exp Med 1987 0.84
31 Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. Cytometry 1998 0.84
32 Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986 0.83
33 Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leuk Lymphoma 2001 0.83
34 Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with similar T-cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis. Blood 1991 0.83
35 A two-color flow cytometry assay for detection of hairy cells using monoclonal antibodies. Blood 1987 0.83
36 Characterization of t(12;21) breakpoint junctions in acute lymphoblastic leukemia. Leukemia 2001 0.82
37 Optimization of a method for simultaneous analysis of cell surface phenotype and cell cycle in human bone marrow and peripheral blood leukocytes by flow cytometry: the value of both internal and external standards. Anal Cell Pathol 1993 0.82
38 Comparison between 125IUdR and 51Cr as cell labels in investigations of tumor cell migration. Int J Rad Appl Instrum B 1990 0.82
39 A quantitative evaluation of erythropoiesis in myelodysplastic syndromes using multiparameter flow cytometry. Leuk Res 1993 0.81
40 Enumeration of organ-associated natural killer cells in mice: application of a new stereological method. APMIS 1992 0.80
41 Immunological studies in chronic lymphocytic leukemia.-II. Natural killer- and antibody-dependent cellular cytotoxicity potentials of malignant and non-malignant lymphocyte subsets and the effect of alpha-interferon. Leuk Res 1981 0.80
42 Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial. J Interferon Res 1984 0.79
43 Malignant monoblasts can function as effector cells in natural killer cell and antibody-dependent cellular cytotoxicity assays. Blood 1981 0.79
44 Natural killer function following allogeneic bone marrow transplantation. Very early reemergence but strong dependence of cytomegalovirus infection. Transplantation 1988 0.79
45 Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. Nucleic Acids Res 1998 0.79
46 Selective effects of alpha interferon on human T-lymphocyte subsets during mixed lymphocyte cultures. Scand J Immunol 1983 0.78
47 Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Br J Haematol 1996 0.78
48 Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 2011 0.78
49 Validation and clinical implication of a quantitative real-time PCR determination of MDR1 gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia. Eur J Haematol 2003 0.78
50 Interferon-induced augmentation of cytotoxic killer cell generation in mixed lymphocyte cultures: analysis of the effector cell product. Scand J Immunol 1981 0.78
51 The use of monoclonal antibodies in clinical haematology--the art of limitation. Scand J Haematol 1984 0.78
52 Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand J Immunol 1998 0.77
53 Human lymphocyte and mouse erythrocyte rosettes. Optimization of the assay. Scand J Haematol 1981 0.77
54 MDR1 gene expression and drug resistance of AML cells. Br J Haematol 1998 0.77
55 Induced and down-regulated proteins in the human cultured hairy cell leukemia line JOK-1 and the Burkitt's lymphoma cell line Daudi during incubation with interferon-alpha: a kinetic study. J Interferon Res 1992 0.77
56 Biology of multiple drug resistance in acute leukemia. Int J Hematol 2000 0.77
57 Immunomodulation of NK and ADCC by Corynebacterium parvum in acute myeloid leukaemia patients. Leuk Res 1985 0.77
58 Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Eur J Haematol 1998 0.77
59 Adjuvant immune stimulation with Corynebacterium parvum during maintenance chemotherapy of acute myeloid leukemia. A prospective randomized study. Cancer Immunol Immunother 1983 0.76
60 Long-term culture of hematopoietic stem cells - validating the stromal component of the CAFC assay. Cytotherapy 2001 0.76
61 Surface expression of the alpha 2-macroglobulin receptor on human malignant blood cells. Leuk Res 1992 0.76
62 Erythropoietin receptor defect: a cause of primary polycythaemia. Br J Haematol 2004 0.76
63 Differential expression levels of the heat shock protein 27 isoforms in pediatric normal, nonleukemic and common acute lymphoblastic leukemia B-cell precursors. Blood 1995 0.76
64 Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant 2000 0.76
65 Effect of psychological intervention in the form of relaxation and guided imagery on cellular immune function in normal healthy subjects. An overview. Psychother Psychosom 1990 0.76
66 Stereological analysis of the ultrastructure in isolated human T and non-T lymphoid cells. I. Description of method and data on normal blood lymphocytes. Virchows Arch B Cell Pathol Incl Mol Pathol 1982 0.76
67 IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives. Cancer Metastasis Rev 1988 0.76
68 Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001 0.76
69 Expression of differentiation and activation antigens on peripheral blood mononuclear cells in chronic lymphocytic leukaemia (CLL) and in hairy-cell leukaemia (HCL) Eur J Haematol 1990 0.75
70 [Scientific reporting--any future development?]. Ugeskr Laeger 1999 0.75
71 [Current therapeutic targeting possibilities in leukemia]. Nord Med 1991 0.75
72 The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. Br J Haematol 1994 0.75
73 DNA preparation from cryopreserved bone marrow cell samples. Anal Biochem 1995 0.75
74 [Diagnosis of minimal residual disease in autologous bone marrow transplantation]. Nord Med 1996 0.75
75 FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001 0.75
76 Prognostic significance of morphologic and cytogenetic findings for progression in myelodysplastic syndromes. Haematol Blood Transfus 1987 0.75
77 Dynamic cell cycle kinetics of normal CD34+ cells and CD38+/- subsets of haemopoietic progenitor cells in G-CSF-mobilized peripheral blood. Br J Haematol 1999 0.75
78 Primary myelodysplastic syndrome: treatment of 6 patients with 13-cis retinoic acid. Scand J Haematol Suppl 1986 0.75
79 Interferon-induced changes in expression of antigens defined by monoclonal antibodies on malignant and nonmalignant mononuclear hematopoietic cells. J Interferon Res 1983 0.75
80 Acid phosphatase and acid esterase activity in neoplastic and non-neoplastic lymphoid cells. A semiquantitative evaluation related to immunological markers in 112 cases. Scand J Haematol 1984 0.75
81 [Immunodiagnosis of lymphoproliferative diseases]. Ugeskr Laeger 1981 0.75
82 Regulation of autologous T-lymphocyte clones on in vitro growth of BFU-e: enhancing effects of both CD4- and CD8-positive clones. Eur J Haematol 1991 0.75
83 Expression and regulation of an interferon-alpha-inducible membrane protein p106 on human hematopoietic cells. J Interferon Res 1993 0.75
84 The relationship between human T-lymphocyte subsets defined by monoclonal antibodies and by avidity differences to sheep erythrocytes. Acta Pathol Microbiol Immunol Scand C 1982 0.75
85 Human peripheral blood lymphocytes. Isolation, subset characterization and in vitro properties. A review of the literature of the 1970s. Acta Pathol Microbiol Scand Suppl 1981 0.75
86 [B and T lymphocytes in the blood]. Ugeskr Laeger 1979 0.75
87 Immunomodulation by Corynebacterium parvum in normal humans. J Immunol 1980 0.75
88 Evolution of Ig- and T-cell receptor gene configuration in a Ph1+ hybrid leukemia patient. Eur J Haematol 1992 0.75
89 First-line diagnosis based on immunological phenotyping in suspected acute leukemia: a prospective study. Leuk Res 1988 0.75
90 Two small lymphocyte subpopulations in human peripheral blood. II. Functional characterization in vitro. Int Arch Allergy Appl Immunol 1978 0.75
91 Measurements of changes in histocompatibility antigens induced by interferons. Methods Enzymol 1986 0.75
92 Reduced total number of cobblestone area forming cells and in vitro stromal-cell growth in autografts from acute myeloid leukemia patients. Cytotherapy 2000 0.75
93 Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study. Nat Immun 1995 0.75
94 Major proteins in normal human lymphocyte subpopulations separated by fluorescence-activated cell sorting and analyzed by two-dimensional gel electrophoresis. Leukemia 1988 0.75
95 Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. Leuk Res 2000 0.75
96 Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data. Eur J Haematol 1988 0.75
97 Thrombocytopenia as a marker for progression in Hodgkin's disease. Eur J Haematol 1998 0.75
98 Effector cell potential of two human T-cell subpopulations with different affinities to sheep erythrocytes. Scand J Immunol 1980 0.75
99 Effects of basic proteins on spontaneous rosette formation between human lymphocytes and xenogeneic erythrocytes. Int Arch Allergy Appl Immunol 1981 0.75
100 Interferon-alpha-induced changes in surface antigens in a hairy-cell leukemia (JOK-1), and a Burkitt's lymphoma cell line (Daudi) during in vitro culture. Eur J Haematol 1992 0.75
101 [Autologous bone marrow transplantation in children with malignant diseases. Bone marrow harvest and procedure-related toxicity]. Ugeskr Laeger 1993 0.75
102 [Hematopoietic stem cells I. Basal aspects]. Ugeskr Laeger 2000 0.75
103 Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia. Leuk Res 1991 0.75
104 The human mixed lymphocyte reaction responder and stimulator capacities of highly purified T- and non-T cells and the role of monocytes. Acta Pathol Microbiol Scand C 1979 0.75
105 [Hematopoietic stem cells II. Diagnostic and therapeutic aspects]. Ugeskr Laeger 2000 0.75
106 Hybrid acute leukemia: therapeutical implications of immunological phenotyping. Anal Cell Pathol 1992 0.75
107 [10 years' experiences with flow cytometric immunological phenotyping in malignant hematologic diseases]. Ugeskr Laeger 1996 0.75
108 Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator Linomide after autologous bone marrow transplantation. Eur J Haematol 1999 0.75
109 Immunoelectron microscopy studies on the modulation of common acute lymphoblastic leukemia antigen (CALLA) on NALM-6 cells: delineation of intracellular transport. Leukemia 1989 0.75
110 Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-alpha-2b treatment. Leuk Res 1989 0.75
111 [Erythropoiesis in myelodysplastic syndrome detected by multiparameter flow cytometry]. Ugeskr Laeger 1995 0.75
112 Immunological studies in chronic lymphocytic leukemia.-I. Elucidation of subset heterogeneity. Leuk Res 1981 0.75
113 Mononuclear cells from peripheral blood of untreated hairy-cell leukaemia patients enhance the growth of BFU-e. Eur J Haematol 1993 0.75
114 The CLL2 study: preliminary results of flow cytometry immunophenotyping in the first 500 patients. Nouv Rev Fr Hematol 1988 0.75
115 Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity. Eur J Haematol 1989 0.75
116 Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol 1999 0.75
117 Improved flow cytometric identification of myelopoiesis by the simultaneous labelling with CD13, CD14 and CD66 monoclonal antibodies. Br J Haematol 1996 0.75
118 Effects of interferon on human lymphoid cells and their function. Ann N Y Acad Sci 1980 0.75
119 Differences in relative DNA content between human peripheral blood and bone marrow subpopulations--consequences for DNA index calculations. Cytometry 1993 0.75
120 Interferons for malignant blood diseases? Eur J Haematol 1987 0.75
121 A novel MLL-AF10 fusion mRNA variant in a patient with acute myeloid leukemia detected by a new asymmetric reverse transcription PCR method. Leukemia 1997 0.75
122 Immunological and molecular biological identification of a true case of T-hairy cell leukaemia. Eur J Haematol 1989 0.75
123 [Natural killer cells in man]. Ugeskr Laeger 1981 0.75
124 [Autologous bone marrow transplantation in malignant blood diseases]. Ugeskr Laeger 1991 0.75
125 Ultrastructure of normal human blood T lymphocyte subsets isolated by cell sorting using monoclonal antibodies. A stereological analysis. Virchows Arch B Cell Pathol Incl Mol Pathol 1982 0.75
126 Clonal T-lymphocytes from untreated hairy-cell leukaemia patients enhance the growth of BFU-E. Eur J Haematol 1994 0.75
127 Secretory products from thrombin-stimulated human platelets exert an inhibitory effect on NK-cytotoxic activity. Acta Pathol Microbiol Immunol Scand C 1986 0.75
128 The interferon/2-5A synthetase system in primary preleukaemia patients. Prog Clin Biol Res 1985 0.75
129 Analysis of the lymphocyte distribution during Isopaque-Ficoll isolation of mononuclear cells from human peripheral blood. J Immunol Methods 1980 0.75
130 Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs. Leuk Res 1993 0.75
131 [Leukocyte differentiation antigens]. Ugeskr Laeger 1983 0.75
132 Functional characterization in vitro of two human T-cell subpopulations with different affinities to sheep erythrocytes. Scand J Immunol 1979 0.75
133 Delineation of erythropoiesis in normal and malignant bone marrow using monoclonal antibody AS-E1 directed against transferrin receptors (CD71). Eur J Haematol 1998 0.75
134 IL-6 might relieve long-standing thrombocytopenia in autotransplanted AML patients. Br J Haematol 1994 0.75
135 Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990 0.75
136 Little evidence for clonal evolution of malignant haematopoietic cells following relapse after autologous bone marrow transplantation. Eur J Haematol 1996 0.75
137 Natural killer cell-mediated inhibition of bone marrow colony formation (CFU-GM) in refractory anaemia (preleukaemia): evidence for patient-specific cell populations. Br J Haematol 1988 0.75
138 Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. Blut 1986 0.75
139 Subclassification in acute lymphoblastic leukaemia: acid phosphatase reaction and immunological markers in relation to clinical features. A comparative study of 44 patients. Scand J Haematol 1981 0.75